Literature DB >> 10495100

Use of meta-analytic results to facilitate shared decision making.

L A Lenert1, D J Cher.   

Abstract

OBJECTIVES: Describe and evaluate an Internet-based approach to patient decision support using mathematical models that predict the probability of successful treatment on the basis of meta-analytic summaries of the mean and standard deviation of symptom response.
DESIGN: An Internet-based decision support tool was developed to help patients with benign prostatic hypertrophy (BPH) determine whether they wanted to use alpha blockers. The Internet site incorporates a meta-analytic model of the results of randomized trials of the alpha blocker terazosin. The site describes alternative treatments for BPH and potential adverse effects of alpha blockers. The site then measures patients' current symptoms and desired level of symptom reduction. In response, the site computes and displays the probability of a patient's achieving his objective by means of terazosin or placebo treatment.
SETTING: Self-identified BPH patients accessing the site over the Internet. MAIN OUTCOME MEASURES: Patients' perceptions of the usefulness of information.
RESULTS: Over a three-month period, 191 patients who were over 50 years of age and who reported that they have BPH used the decision support tool. Respondents had a mean American Urological Association (AUA) score of 18.8 and a desired drop in symptoms of 10.1 AUA points. Patients had a 40 percent chance of achieving treatment goals with terazosin and a 20 percent chance with placebo. Patients found the information useful (93 percent), and most (71 percent) believed this type of information should be discussed before prescribing medications.
CONCLUSIONS: Interactive meta-analytic summary models of the effects of pharmacologic treatments can help patients determine whether a treatment offers sufficient benefits to offset its risks.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10495100      PMCID: PMC61383          DOI: 10.1136/jamia.1999.0060412

Source DB:  PubMed          Journal:  J Am Med Inform Assoc        ISSN: 1067-5027            Impact factor:   4.497


  18 in total

1.  The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association.

Authors:  M J Barry; F J Fowler; M P O'Leary; R C Bruskewitz; H L Holtgrewe; W K Mebust; A T Cockett
Journal:  J Urol       Date:  1992-11       Impact factor: 7.450

2.  Relationship of symptoms of prostatism to commonly used physiological and anatomical measures of the severity of benign prostatic hyperplasia.

Authors:  M J Barry; A T Cockett; H L Holtgrewe; J D McConnell; S A Sihelnik; H N Winfield
Journal:  J Urol       Date:  1993-08       Impact factor: 7.450

3.  Safety and efficacy of doxazosin in benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies.

Authors:  C G Roehrborn; R L Siegel
Journal:  Urology       Date:  1996-09       Impact factor: 2.649

4.  Use of terazosin in the medical treatment of benign prostatic hyperplasia: experience in Italy.

Authors:  F Di Silverio
Journal:  Br J Urol       Date:  1992-11

5.  Terazosin in the treatment of benign prostatic hyperplasia: a multicentre, placebo-controlled trial.

Authors:  S N Lloyd; J F Buckley; C P Chilton; I Ibrahim; A V Kaisary; D Kirk
Journal:  Br J Urol       Date:  1992-11

6.  Terazosin in the treatment of benign prostatic hyperplasia. Terazosin Benign Prostatic Hyperplasia Study Group.

Authors:  M K Brawer; G Adams; H Epstein
Journal:  Arch Fam Med       Date:  1993-09

7.  Benign prostatic hyperplasia: diagnosis and treatment. Agency for Health Care Policy and Research.

Authors:  J D McConnell; M J Barry; R C Bruskewitz
Journal:  Clin Pract Guidel Quick Ref Guide Clin       Date:  1994-02

8.  Correlation of the American Urological Association symptom index with self-administered versions of the Madsen-Iversen, Boyarsky and Maine Medical Assessment Program symptom indexes. Measurement Committee of the American Urological Association.

Authors:  M J Barry; F J Fowler; M P O'Leary; R C Bruskewitz; H L Holtgrewe; W K Mebust
Journal:  J Urol       Date:  1992-11       Impact factor: 7.450

9.  A randomized, placebo-controlled multicenter study of the efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia.

Authors:  H Lepor; S Auerbach; A Puras-Baez; P Narayan; M Soloway; F Lowe; T Moon; G Leifer; P Madsen
Journal:  J Urol       Date:  1992-11       Impact factor: 7.450

10.  The use of alpha-adrenergic blockers in benign prostatic obstruction.

Authors:  M Caine; A Pfau; S Perlberg
Journal:  Br J Urol       Date:  1976-08
View more
  16 in total

1.  Randomized testing of alternative survey formats using anonymous volunteers on the World Wide Web.

Authors:  D S Bell; C M Mangione; C E Kahn
Journal:  J Am Med Inform Assoc       Date:  2001 Nov-Dec       Impact factor: 4.497

2.  Use of the internet to study the utility values of the public.

Authors:  Leslie A Lenert; Ann E Sturley
Journal:  Proc AMIA Symp       Date:  2002

3.  Bridging the gap between therapeutic research results and physician prescribing decisions: knowledge transfer, a prerequisite to knowledge translation.

Authors:  Jean-Pierre Boissel; Emmanuel Amsallem; Michel Cucherat; Patrice Nony; Margaret C Haugh
Journal:  Eur J Clin Pharmacol       Date:  2004-09-16       Impact factor: 2.953

Review 4.  Rethinking health numeracy: a multidisciplinary literature review.

Authors:  Jessica S Ancker; David Kaufman
Journal:  J Am Med Inform Assoc       Date:  2007-08-21       Impact factor: 4.497

5.  Effect of arrangement of stick figures on estimates of proportion in risk graphics.

Authors:  Jessica S Ancker; Elke U Weber; Rita Kukafka
Journal:  Med Decis Making       Date:  2010-07-29       Impact factor: 2.583

6.  The stadium diagram, a web-based tool for visualizing the expected outcomes of alternative clinical management strategies.

Authors:  Douglas S Bell; Steven Sobolevsky; Frank C Day; Jerome R Hoffman; Jerilyn K Higa; Michael S Wilkes
Journal:  AMIA Annu Symp Proc       Date:  2005

7.  Representing randomness in the communication of individualized cancer risk estimates: effects on cancer risk perceptions, worry, and subjective uncertainty about risk.

Authors:  Paul K J Han; William M P Klein; Bill Killam; Tom Lehman; Holly Massett; Andrew N Freedman
Journal:  Patient Educ Couns       Date:  2011-03-05

Review 8.  Design features of graphs in health risk communication: a systematic review.

Authors:  Jessica S Ancker; Yalini Senathirajah; Rita Kukafka; Justin B Starren
Journal:  J Am Med Inform Assoc       Date:  2006-08-23       Impact factor: 4.497

9.  What is the next step in patient decision support?

Authors:  G C Scott; L A Lenert
Journal:  Proc AMIA Symp       Date:  2000

10.  Assessing multiple medication use with probabilities of benefits and harms.

Authors:  Terrence E Murphy; Joseph V Agostini; Peter H Van Ness; Peter Peduzzi; Mary E Tinetti; Heather G Allore
Journal:  J Aging Health       Date:  2008-07-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.